21-May-2024
No headlines found.
Ocular Therapeutix Reports First Quarter 2024 Results
Globe Newswire (Tue, 7-May 4:05 PM ET)
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Mon, 6-May 8:16 PM ET)
Ocular Therapeutix to Present at Two Upcoming Investor Conferences
Globe Newswire (Mon, 6-May 7:30 AM ET)
Ocular Therapeutix To Present at Two Ophthalmology Meetings, May 4-9, 2024
Globe Newswire (Fri, 3-May 7:30 AM ET)
Ocular Therapeutix to Host Investor Day in New York City on Thursday, June 13, 2024
Globe Newswire (Wed, 1-May 7:30 AM ET)
Ocular Therapeutix Announces Positive Topline Phase 1 Data for AXPAXLI in Diabetic Retinopathy
Globe Newswire (Thu, 18-Apr 7:00 AM ET)
Ocular Therapeutix Strengthens Clinical Team with Appointment of Key Retinal Leaders
Globe Newswire (Tue, 16-Apr 7:00 AM ET)
Globe Newswire (Mon, 15-Apr 7:00 AM ET)
Globe Newswire (Tue, 9-Apr 7:30 AM ET)
Globe Newswire (Sat, 6-Apr 10:00 AM ET)
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Ocular Therapeutix trades on the NASDAQ stock market under the symbol OCUL.
As of May 21, 2024, OCUL stock price declined to $6.10 with 1,439,276 million shares trading.
OCUL has a beta of 2.24, meaning it tends to be more sensitive to market movements. OCUL has a correlation of 0.06 to the broad based SPY ETF.
OCUL has a market cap of $944.82 million. This is considered a Small Cap stock.
Last quarter Ocular Therapeutix reported $15 million in Revenue and -$.28 earnings per share. This fell short of revenue expectation by $-636,000 and missed earnings estimates by -$.09.
In the last 3 years, OCUL stock traded as high as $15.32 and as low as $2.00.
The top ETF exchange traded funds that OCUL belongs to (by Net Assets): VTI, IWM, VXF, IWO, DWAS.
OCUL has underperformed the market in the last year with a return of -5.6%, while the SPY ETF gained +28.5%. In the last 3 month period, OCUL fell short of the market, returning -18.9%, while SPY returned +7.3%. However, in the most recent 2 weeks OCUL has outperformed the stock market by returning +5.2%, while SPY returned +2.9%.
OCUL support price is $5.83 and resistance is $6.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OCUL stock will trade within this expected range on the day.